|
1) Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008; 7: 489-503
|
|
|
|
2) Haunerland NH, Spener F. Fatty acid-binding proteins--insights from genetic manipulations. Prog Lipid Res. 2004; 43: 328-49
|
|
|
|
|
|
3) Shum BO, Mackay CR, Görgün CZ, et al. The adipocyte fatty acid-binding protein aP2 is required in allergic airway inflammation. J Clin Invest. 2006; 116: 2183-92
|
|
|
|
|
|
4) Hotamisligil GS, Johnson RS, Distel RJ, et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science. 1996; 274: 1377–9
|
|
|
|
|
|
5) Uysal KT, Scheja L, Wiesbrock SM, et al. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology. 2000; 141: 3388–96
|
|
|
|
|
|
6) Makowski L, Boord JB, Maeda K, et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med. 2001; 7: 699–705
|
|
|
|
|
|
7) Furuhashi M, Tuncman G, Görgün CZ, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature. 2007; 447: 959-65
|
|
|
|
|
|
8) Fu Y, Luo N, Lopes-Virella MF, et al. The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis. 2002; 165: 259–69
|
|
|
|
|
|
9) Tuncman G, Erbay E, Hom X, et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci U S A. 2006; 103: 6970–5
|
|
|
|
|
|
10) Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem. 2006; 52: 405-13
|
|
|
|
|
|
11) Tso AW, Xu A, Sham PC, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care. 2007; 30: 2667-72
|
|
|
|
|
|
12) Maeda K, Uysal KT, Makowski L, et al. Role of the fatty acid binding protein mal1 in obesity and insulin resistance. Diabetes. 2003; 52: 300-7
|
|
|
|
|
|
13) Maeda K, Cao H, Kono K, et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab. 2005; 1: 107-19
|
|
|
|
|
|
14) Boord JB, Maeda K, Makowski L, et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation. 2004; 110: 1492-8
|
|
|
|
|
|
15) Furuhashi M, Fucho R, Görgün CZ, et al. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest. 2008; 118: 2640-50
|
|
|
|
|
|
16) Cao H, Gerhold K, Mayers JR, et al. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 2008; 134: 933-44
|
|
|
|
|
|
17) Erbay E, Babaev VR, Mayers JR, et al. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med. 2009; 15: 1383-91
|
|
|
|
|
|
18) Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007; 8: 519-29
|
|
|
|
|
|
19) Zhang K, Kaufman RJ. From endoplasmic-reticulum stress to the inflammatory response. Nature. 2008; 454: 455-62
|
|
|
|
|
|
20) Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell. 2010; 140: 900-17
|
|
|
|
|
|
21) Iwawaki T, Akai R, Kohno K, et al. A transgenic mouse model for monitoring endoplasmic reticulum stress. Nat Med. 2004; 10: 98-102
|
|
|
|
|
|
22) Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004; 306: 457-61
|
|
|
|
|
|
23) Nakatani Y, Kaneto H, Kawamori D, et al. Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. J Biol Chem. 2005; 280: 847-51
|
|
|
|
|
|
24) Winnay JN, Boucher J, Mori MA, et al. A regulatory subunit of phosphoinositide 3-kinase increases the nuclear accumulation of X-box-binding protein-1 to modulate the unfolded protein response. Nat Med. 2010; 16: 438-45
|
|
|
|
|
|
25) Park SW, Zhou Y, Lee J, et al. The regulatory subunits of PI3K, p85alpha and p85beta, interact with XBP-1 and increase its nuclear translocation. Nat Med. 2010; 16: 429-37
|
|
|
|
|
|
26) Delépine M, Nicolino M, Barrett T, et al. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet. 2000; 25: 406-9
|
|
|
|
|
|
27) Harding HP, Zeng H, Zhang Y, et al. Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol Cell. 2001; 7: 1153-63
|
|
|
|
|
|
28) Zhang P, McGrath B, Li S, et al. The PERK eukaryotic initiation factor 2 alpha kinase is required for the development of the skeletal system, postnatal growth, and the function and viability of the pancreas. Mol Cell Biol. 2002; 22: 3864-74
|
|
|
|
|
|
29) Zhang W, Feng D, Li Y, et al. PERK EIF2AK3 control of pancreatic beta cell differentiation and proliferation is required for postnatal glucose homeostasis. Cell Metab. 2006; 4: 491-7
|
|
|
|
|
|
30) Scheuner D, Song B, McEwen E, et al. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell. 2001; 7: 1165-76
|
|
|
|
|
|
31) Scheuner D, Mierde DV, Song B, et al. Control of mRNA translation preserves endoplasmic reticulum function in beta cells and maintains glucose homeostasis. Nat Med. 2005; 11: 757-64
|
|
|
|
|
|
32) Nakamura T, Furuhashi M, Li P, et al. Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell. 2010; 140: 338-48
|
|
|
|
|
|
33) Ozawa K, Miyazaki M, Matsuhisa M, et al. The endoplasmic reticulum chaperone improves insulin resistance in type 2 diabetes. Diabetes. 2005; 54: 657-63
|
|
|
|
|
|
34) Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006; 313: 1137-40
|
|
|
|
|
|
35) Ozcan L, Ergin AS, Lu A, et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009; 9: 35-51
|
|
|
|
|
|
36) Kars M, Yang L, Gregor MF, et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010; 59: 1899-905
|
|
|
|
|